Some notes from the study that looked at the breast cancer fighting drugs Tamoxifen and Raloxifene.
- 19,000 participated, 250 of them at Pratt Cancer Center at St. Johns.
- In preventing breast cancer among women at risk, Tamoxifen was 50% effective and Raloxifene was 38% effective.
- Both drugs have the side effect of developing blood clots by up to three times.
- Tamoxifen increases the chances of developing uterine cancer by two or three times, while Raloxifene showed 45% fewer uterine cancers during the trial.
- Both drugs however are know to be effective in fighting osteoperosis.